Articles related to OBESITY/WEIGHT MANAGEMENT

Semaglutide may alter taste perception gene expression in the tongue and modify brain reactions to sweet tastes, potentially enhancing weight loss effects beyond appetite suppression.

Semaglutide treatment led to more frequent improvement and less frequent deterioration in NYHA functional class compared to placebo in patients with obesity-related HFpEF over 52 weeks.

Lymphedema and lipedema, while superficially similar, have distinct pathophysiologies and management strategies. Understanding these differences is essential for providing targeted care and improving patient outcomes.

Patients taking semaglutide for diabetes were more than four times more likely to develop NAION compared to those on other diabetes medications, while those using it for obesity had a seven-fold increased risk.

Rapid weight loss from semaglutide use can lead to breast ptosis, mirroring effects seen after bariatric surgery. Healthcare providers should be prepared to counsel patients on this potential outcome and offer strategies for management.

This target trial emulation study provides critical insights into weight change associated with eight first-line antidepressants, emphasizing the minimal weight gain with bupropion. Clinicians should integrate these findings into treatment decisions to address patient concerns about weight gain.